Size exclusion chromatography as green support for forced degradation study of adalimumab

Size exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventiona...

Full description

Saved in:
Bibliographic Details
Main Authors: Kovačić Jelena, Klarić Daniela Amidžić, Turk Nikša, Mornar Ana
Format: Article
Language:English
Published: Sciendo 2023-12-01
Series:Acta Pharmaceutica
Subjects:
Online Access:https://doi.org/10.2478/acph-2023-0044
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545929268297728
author Kovačić Jelena
Klarić Daniela Amidžić
Turk Nikša
Mornar Ana
author_facet Kovačić Jelena
Klarić Daniela Amidžić
Turk Nikša
Mornar Ana
author_sort Kovačić Jelena
collection DOAJ
description Size exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC.
format Article
id doaj-art-780f2056885f45faa158c1c59dcb6b0e
institution Kabale University
issn 1846-9558
language English
publishDate 2023-12-01
publisher Sciendo
record_format Article
series Acta Pharmaceutica
spelling doaj-art-780f2056885f45faa158c1c59dcb6b0e2025-02-03T07:24:17ZengSciendoActa Pharmaceutica1846-95582023-12-0173470972110.2478/acph-2023-0044Size exclusion chromatography as green support for forced degradation study of adalimumabKovačić Jelena0Klarić Daniela Amidžić1Turk Nikša2Mornar Ana31University of Zagreb, Faculty of Pharmacy and Biochemistry Department of Pharmaceutical Analysis, 10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry Department of Pharmaceutical Analysis, 10000Zagreb, Croatia2Clinical Hospital ZagrebDepartment of Gastroenterology, 10000ZagrebCroatia1University of Zagreb, Faculty of Pharmacy and Biochemistry Department of Pharmaceutical Analysis, 10000Zagreb, CroatiaSize exclusion chromatography (SEC) has become a powerful tool for analysing size variants of biologic drugs in their native form. Modern SEC can be defined by the use of chromatographic columns packed with sub-3 µm particles, allowing an increase in method throughput compared to that of conventional SEC.https://doi.org/10.2478/acph-2023-0044inflammatory bowel diseasebiopharmaceuticalsadalimumabsize exclusion chromatographyforced degradation study
spellingShingle Kovačić Jelena
Klarić Daniela Amidžić
Turk Nikša
Mornar Ana
Size exclusion chromatography as green support for forced degradation study of adalimumab
Acta Pharmaceutica
inflammatory bowel disease
biopharmaceuticals
adalimumab
size exclusion chromatography
forced degradation study
title Size exclusion chromatography as green support for forced degradation study of adalimumab
title_full Size exclusion chromatography as green support for forced degradation study of adalimumab
title_fullStr Size exclusion chromatography as green support for forced degradation study of adalimumab
title_full_unstemmed Size exclusion chromatography as green support for forced degradation study of adalimumab
title_short Size exclusion chromatography as green support for forced degradation study of adalimumab
title_sort size exclusion chromatography as green support for forced degradation study of adalimumab
topic inflammatory bowel disease
biopharmaceuticals
adalimumab
size exclusion chromatography
forced degradation study
url https://doi.org/10.2478/acph-2023-0044
work_keys_str_mv AT kovacicjelena sizeexclusionchromatographyasgreensupportforforceddegradationstudyofadalimumab
AT klaricdanielaamidzic sizeexclusionchromatographyasgreensupportforforceddegradationstudyofadalimumab
AT turkniksa sizeexclusionchromatographyasgreensupportforforceddegradationstudyofadalimumab
AT mornarana sizeexclusionchromatographyasgreensupportforforceddegradationstudyofadalimumab